vs
Side-by-side financial comparison of AmpliTech Group, Inc. (AMPG) and Bolt Biotherapeutics, Inc. (BOLT). Click either name above to swap in a different company.
AmpliTech Group, Inc. is the larger business by last-quarter revenue ($4.5M vs $2.5M, roughly 1.8× Bolt Biotherapeutics, Inc.). AmpliTech Group, Inc. runs the higher net margin — -71.6% vs -265.2%, a 193.6% gap on every dollar of revenue. Over the past eight quarters, AmpliTech Group, Inc.'s revenue compounded faster (39.7% CAGR vs -31.2%).
Ampli Energy is a South African company providing a renewable energy trading platform that uses a wheeling process to deliver green energy to consumers.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
AMPG vs BOLT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5M | $2.5M |
| Net Profit | $-3.2M | $-6.6M |
| Gross Margin | 22.8% | — |
| Operating Margin | -73.3% | -283.4% |
| Net Margin | -71.6% | -265.2% |
| Revenue YoY | 141.6% | — |
| Net Profit YoY | 16.1% | 58.4% |
| EPS (diluted) | $-0.14 | $-9.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.5M | $2.5M | ||
| Q3 25 | $6.1M | $2.2M | ||
| Q2 25 | $11.0M | $1.8M | ||
| Q1 25 | $3.6M | $1.2M | ||
| Q4 24 | $1.9M | $0 | ||
| Q3 24 | $2.8M | $1.1M | ||
| Q2 24 | $2.5M | $1.3M | ||
| Q1 24 | $2.3M | $5.3M |
| Q4 25 | $-3.2M | $-6.6M | ||
| Q3 25 | $-188.4K | $-7.1M | ||
| Q2 25 | $-1.8M | $-8.6M | ||
| Q1 25 | $-1.8M | $-11.0M | ||
| Q4 24 | $-3.8M | $-15.9M | ||
| Q3 24 | $-1.2M | $-15.2M | ||
| Q2 24 | $-1.6M | $-21.2M | ||
| Q1 24 | $-4.7M | $-10.8M |
| Q4 25 | 22.8% | — | ||
| Q3 25 | 48.6% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 33.0% | — | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 47.6% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 38.5% | — |
| Q4 25 | -73.3% | -283.4% | ||
| Q3 25 | -3.6% | -355.1% | ||
| Q2 25 | -17.5% | -510.5% | ||
| Q1 25 | -52.5% | -991.4% | ||
| Q4 24 | -234.5% | — | ||
| Q3 24 | -38.4% | -1441.1% | ||
| Q2 24 | -62.0% | -1772.3% | ||
| Q1 24 | -62.3% | -324.1% |
| Q4 25 | -71.6% | -265.2% | ||
| Q3 25 | -3.1% | -329.4% | ||
| Q2 25 | -16.1% | -474.6% | ||
| Q1 25 | -51.1% | -903.4% | ||
| Q4 24 | -206.2% | — | ||
| Q3 24 | -42.0% | -1330.1% | ||
| Q2 24 | -62.4% | -1662.4% | ||
| Q1 24 | -203.0% | -205.0% |
| Q4 25 | $-0.14 | $-9.38 | ||
| Q3 25 | $-0.01 | $-3.72 | ||
| Q2 25 | $-0.09 | $-4.46 | ||
| Q1 25 | $-0.09 | $-0.29 | ||
| Q4 24 | $-0.28 | $-13.73 | ||
| Q3 24 | $-0.12 | $-7.93 | ||
| Q2 24 | $-0.16 | $-11.12 | ||
| Q1 24 | $-0.48 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $27.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $32.9M | $26.5M |
| Total Assets | $51.5M | $56.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $27.5M | ||
| Q3 25 | $8.4M | $31.9M | ||
| Q2 25 | $11.1M | $34.8M | ||
| Q1 25 | $16.9M | $38.8M | ||
| Q4 24 | $19.3M | $47.3M | ||
| Q3 24 | $1.1M | $53.8M | ||
| Q2 24 | $1.0M | $73.7M | ||
| Q1 24 | $2.4M | $91.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $36.4K | — | ||
| Q1 24 | $63.2K | — |
| Q4 25 | $32.9M | $26.5M | ||
| Q3 25 | $35.8M | $32.1M | ||
| Q2 25 | $35.8M | $38.8M | ||
| Q1 25 | $35.8M | $46.8M | ||
| Q4 24 | $37.5M | $57.2M | ||
| Q3 24 | $20.4M | $72.0M | ||
| Q2 24 | $20.7M | $85.9M | ||
| Q1 24 | $22.2M | $104.2M |
| Q4 25 | $51.5M | $56.7M | ||
| Q3 25 | $47.2M | $65.1M | ||
| Q2 25 | $48.6M | $75.5M | ||
| Q1 25 | $42.1M | $85.9M | ||
| Q4 24 | $43.2M | $99.6M | ||
| Q3 24 | $27.5M | $109.3M | ||
| Q2 24 | $25.4M | $124.2M | ||
| Q1 24 | $26.9M | $142.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.4M | $-7.2M |
| Free Cash FlowOCF − Capex | $-3.5M | — |
| FCF MarginFCF / Revenue | -78.4% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.4M | $-7.2M | ||
| Q3 25 | $-999.4K | $-9.7M | ||
| Q2 25 | $-2.3M | $-9.6M | ||
| Q1 25 | $-2.0M | $-13.4M | ||
| Q4 24 | $-1.2M | $-14.4M | ||
| Q3 24 | $-1.7M | $-14.0M | ||
| Q2 24 | $-1.3M | $-16.1M | ||
| Q1 24 | $-1.1M | $-16.8M |
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-2.4M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.7M | $-14.0M | ||
| Q2 24 | $-1.3M | — | ||
| Q1 24 | $-1.1M | — |
| Q4 25 | -78.4% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -65.8% | — | ||
| Q4 24 | -63.9% | — | ||
| Q3 24 | -61.6% | -1227.6% | ||
| Q2 24 | -52.7% | — | ||
| Q1 24 | -47.0% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.4% | 3.6% | ||
| Q2 24 | 0.5% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPG
| Other | $2.7M | 60% |
| Distribution | $1.8M | 40% |
BOLT
Segment breakdown not available.
